Our Take
This is a regulatory approval, not a clinical finding; the trial data matters more than the EC stamp, and the real test is reimbursement adoption across 30 countries.
Why it matters
Oncologists treating cisplatin-ineligible MIBC patients now have a first-in-class option combining a checkpoint inhibitor with an antibody-drug conjugate. Reimbursement decisions in each EU nation will determine whether that approval translates to patient access.
Do this week
Reimbursement teams: file health economic dossiers in your priority markets before Q4 so payers can complete assessment cycles and enable Q1 2027 launch readiness.
EC greenlights the first PD-1/ADC combination for early bladder cancer
The European Commission has approved Merck's Keytruda (pembrolizumab) in combination with Pfizer and Astellas' Padcev (enfortumab vedotin-ejfv) as a neoadjuvant treatment for adults with resectable muscle-invasive bladder cancer (MIBC) who cannot tolerate cisplatin-based chemotherapy. The approval applies across all 27 EU member states, Iceland, Liechtenstein, and Norway.
This marks the first time a PD-1 inhibitor and an antibody-drug conjugate have been approved together in this patient population anywhere in Europe. The decision follows a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use in May 2026. Both drugs already carry US FDA approval for the same indication (November 2025).
The Phase III evidence
The approval rests on data from the KEYNOTE-905/EV-303 trial, which enrolled 595 patients. Patients receiving Keytruda plus Padcev before surgery showed:
- 60% reduction in event-free survival risk versus surgery alone; median EFS not reached for the combination versus 15.7 months for surgery alone (per company-reported trial data)
- 50% reduction in death risk (company-reported)
- Pathologic complete response rate of 57.1% with the combination versus 8.6% for surgery alone (company-reported)
The trial is ongoing and evaluating multiple sequences and combinations of perioperative treatments.
The approval gap: what EC greenlight does not guarantee
Regulatory approval and patient access are not the same thing. While the EC decision is necessary, commercial availability in each country depends on completion of national reimbursement processes. In practice, this means 30 separate health authority assessments, each with its own cost-effectiveness threshold, budget constraints, and negotiation cycles.
The EFS and overall survival gains are clinically meaningful by oncology standards. A 60% reduction in event-free survival risk and a 50% reduction in mortality represent material improvements in a disease with limited treatment options for cisplatin-ineligible patients. However, the real-world adoption question is whether national payers will fund a dual-agent regimen at a price point that makes sense in their healthcare systems.
Merck has already secured US coverage and reimbursement paths (the combination approved there in November 2025). European adoption timelines will depend heavily on Merck's pricing strategy and each country's health economic review process.
What happens next
For reimbursement and market access teams, the next 90 days are critical. National health authorities in France, Germany, the UK, Italy, Spain, and other major markets will now begin formal health economic assessments. Companies need to file dossiers that address cost-effectiveness ratios, budget impact, and comparative positioning against other neoadjuvant options (such as cisplatin-eligible regimens or checkpoint inhibitor monotherapy).
Oncology practices in EU countries should expect gradual formulary and guideline updates as reimbursement decisions roll out country by country. The approval itself creates no immediate prescribing obligation; payer decisions do.
This approval also signals Merck's continued momentum in bladder cancer. Earlier in June, Merck received FDA approval for Keytruda and Keytruda Qlex in combination with Welireg (belzutifan) for adjuvant renal cell carcinoma—a separate indication showing portfolio depth in uro-oncology.